The European Chemicals Agency's (ECHA) Biocidal Products Committee (BPC) has noted an increase in the number of opinions rejecting active substance approvals and Union authorisations due to incomplete data submissions. In its recent May meeting, the BPC adopted opinions on four active substances and seven Union authorisations.

The committee supported the renewal of dinotefuran for product-type 18 (insecticides, acaricides, and other arthropod control products) and the approval of polymeric betaine for product-type 8 (wood preservatives). However, it did not support the renewal of medetomidine for product-type 21 (antifouling products) and the approval of 5-Chloro-2-methyl-2H-isothiazol-3-one (CIT) for product-type 6 (preservatives for products during storage).

Among the seven opinions on Union authorisations, the BPC endorsed the following:

• A biocidal product containing propan-2-ol for product-type 2 (disinfectants and algaecides not intended for direct application to humans or animals).
• A biocidal product family containing propan-1-ol and propan-2-ol for product-type 1 (disinfectants for human hygiene).
• A biocidal product family containing Margosa extract for product-type 19 (repellents and attractants for pest control).
• A biocidal product containing Glutaral (Glutaraldehyde) and a reaction mass of 5-chloro-2-methyl-2h-isothiazol-3-one and 2-methyl-2h-isothiazol-3-one (3:1) for product-types 6, 11 (preservatives for liquid-cooling and processing systems), and 12 (slimicides).
• A biocidal product family containing a reaction mass of 5-chloro-2-methyl-2h-isothiazol-3-one and 2-methyl-2h-isothiazol-3-one (3:1) for product-types 4 (disinfectants for food and feed areas), 11, and 12.
• A biocidal product family containing peracetic acid for product-types 2, 3 (disinfectants for veterinary hygiene), and 4.

The BPC did not support the authorisation of a product family containing hydrogen peroxide for product-type 4.

Evaluating Member States recommend non-approvals and non-authorisations when companies fail to submit the required data, such as information on efficacy or endocrine disruption, within the specified deadlines. As a result, the BPC's opinion will not be favourable in such cases.